Paolo Bernasconi

University of Pavia — Italy

Medicine · Health Sciences

43h-index7.5kcitations399works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(113), Chronic Myeloid Leukemia Treatments(68), Hematopoietic Stem Cell Transplantation(55), Chronic Lymphocytic Leukemia Research(53), Acute Lymphoblastic Leukemia research(47)

Publications398 total

Progressive Multifocal Leukoencephalopathy (PML) after hematopoietic cell transplantation (HCT): a retrospective study of Infectious Diseases Working Party (IDWP) of the EBMT
Bone Marrow Transplantation·2025· 1 citedOpen Access
Donor-specific anti-HLA antibodies (DSAs) in patients undergoing allogeneic hematopoietic stem cell transplantation from mismatched donors on behalf of GITMO and AIBT.
PubMed·2025Open Access
Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial
Blood Advances·2025· 6 citedOpen Access
Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation
Transplantation and Cellular Therapy·2024
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial
Blood Cancer Journal·2024· 7 citedOpen Access
Busulfan-Fludarabine Versus Busulfan-Cyclophosphamide for Allogeneic Transplant in Acute Myeloid Leukemia: Long Term Analysis of GITMO AML-R2 Trial
2024Open Access
Comparative efficacy and safety of first-line tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and network meta-analysis
Translational Cancer Research·2024· 5 citedOpen Access
Donor Cell Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease: A Case Report and Literature Review
Genes·2023· 1 citedOpen Access
Human Cytomegalovirus (HCMV) - specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients
Journal of Clinical Virology·2023· 11 cited
P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
HemaSphere·2023Open Access
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study
Transplantation Direct·2023· 10 citedOpen Access
1070 PROGNOSTIC PERFORMANCE OF CARDIAC MAGNETIC RESONANCE IMAGING MARKERS VERSUS COMPLICATED CLINICAL PRESENTATION AFTER AN ACUTE MYOCARDITIS
European Heart Journal Supplements·2022Open Access
Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study
Blood·2022· 1 cited
Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia
Blood·2022
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01
Bone Marrow Transplantation·2022· 11 citedOpen Access
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT
Bone Marrow Transplantation·2022· 23 cited
GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms
Transplantation and Cellular Therapy·2021· 30 citedOpen Access
Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study
Blood·2021
Eradication of Measurable Residual Disease in AML: A Challenging Clinical Goal
Cancers·2021· 14 citedOpen Access
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
Leukemia·2021· 70 citedOpen Access
page 1 of 20Next →

Frequent Co-authors

Mario Lazzarino(22), Marina Boni(12), Enrica Morra(10), Cristiana Pascutto(8), Francesco Passamonti(8), A. Colombo(8), Carlo Bernasconi(8), Silvia Calatroni(8), Luca Malcovati(7), Mario Cazzola(7), Ercole Brusamolino(7), Luca Arcaini(6), Giovanni Martinelli(6), Matteo Giovanni Della Porta(5), Catherine Klersy(5), G. Pagnucco(5), Ilaria Giardini(5), Barbara Rocca(5), Marilena Caresana(5), C Bernasconi(5)